Pediatrics Doctors in Ukiah, CA Accepting Medicare

9 Pediatrics doctors found. Showing 1 - 9

Anne Catherine Martin-ko, MD Pediatrics - Adolescent Medicine Medicare: Medicare Enrolled Practice Location: 260 Hospital Dr, Suite 204, Ukiah, CA 95482 Phone: 707-463-3470

Ms. Shaista Parveen, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 260 Hospital Dr, Suite 204, Ukiah, CA 95482 Phone: 707-463-8000    Fax: 707-462-1111

Dr. Kirsten Quitno Juliet, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 260 Hospital Dr, Ukiah, CA 95482 Phone: 707-463-8000    Fax: 707-462-1111

Julia Regina Katsuura, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 260 Hospital Dr Ste 204, Ukiah, CA 95482 Phone: 707-463-7459

Geata Raguparan, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 260 Hospital Dr, Suite 204, Ukiah, CA 95482 Phone: 707-463-8000    Fax: 707-462-1111

Casey A Johnston, M.D Pediatrics Medicare: Medicare Enrolled Practice Location: 260 Hospital Dr, Suite 204, Ukiah, CA 95482 Phone: 707-463-8032

Dr. Brynn Robert Stirling, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 260 Hospital Dr, Suite 204, Ukiah, CA 95482 Phone: 707-463-7600    Fax: 707-462-1111

Dr. Samuel Goldberg, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 260 Hospital Dr, Ukiah, CA 95482 Phone: 707-463-8000    Fax: 707-462-1111

Dr. Jeremy S Mann, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 260 Hospital Dr, Ukiah, CA 95482 Phone: 707-463-8000    Fax: 707-462-1111

News Archive

CanSino's potential coronavirus vaccine triggers immune response in clinical trial

Scientists across the globe are racing to develop a vaccine that can provide protection against coronavirus disease (COVID-19). An effective and safe vaccine would curb not only the current coronavirus pandemic but also prevent future outbreaks

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

BioMarin Pharmaceutical Inc. today announced an update on the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage disorder Mucopolysaccharidosis Type IVA (MPS IVA), or Morquio A Syndrome. Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0 mg/kg) have been evaluated, and BioMarin plans to announce top-line results for the full 36-week study after completion of dosing at 2.0 mg/kg in the second quarter of 2010.

UC associate professor receives NCI grant to study small RNAs in breast cancer metastasis

Xiaoting Zhang, PhD, associate professor of cancer biology at the University of Cincinnati College of Medicine, received federal funding, an R01 grant from the National Cancer Institute, to study certain genetic material, known as small RNAs, in breast cancer metastasis (or spread).

Community care helps schizophrenia patients in resource-poor settings

Collaborative care delivered by community health workers can improve outcomes among patients with schizophrenia receiving facility-based case in resource-poor settings, shows a study in The Lancet.

Alzheimer's Foundation of America applauds dementia-related provisions in health reform law

The Alzheimer's Foundation of America (AFA) is extremely pleased that the historic health reform signed into law by President Obama late this morning, after passing the U.S. House of Representatives on Sunday and the U.S. Senate in December, includes a number of provisions that are especially significant for AFA's constituents—and bode well for improving quality of life for individuals with Alzheimer's disease and related dementias, and their family caregivers. In particular, we are grateful that the final action addresses many of the practical and financial needs faced daily by this population, speaks to preventative issues and bolsters training of dementia care professionals.

Read more Medical News

› Verified 8 days ago